Drug Development · global
Phase 3 Trial Reaches the Finish Line, but No Filing Follows: Sanofi Ends Amlitelimab Development in Atopic Dermatitis
The OX40L antibody had shown the potential for durable efficacy and infrequent dosing, but after assessing the efficacy and safety evidence as a whole, Sanofi concluded that it was insufficient to clearly surpass existing treatments; full phase 3 data have yet to be disclosed.
Even if a new drug meets some efficacy endpoints in a phase 3 trial, it may not make it to market. Sanofi announced that it is discontinuing the clinical development of amlitelimab for moderate-to-severe atopic dermatitis and will not seek approval from regulatory authorities worldwide. The key issue is not that the company claims the drug has no effect, but that the overall evidence is insufficient to show that it can deliver a meaningful advance over existing care.
Amlitelimab is a fully human monoclonal antibody targeting the immune-regulating molecule OX40 ligand (OX40L). It is designed to block signaling further upstream in the overactive immune response, modulating T-cell-mediated inflammation without depleting T cells. This pathway differs from those of existing biologics targeting IL-4 and IL-13 and JAK inhibitors, and had been expected to offer another way to control chronic skin inflammation.
Sanofi said the phase 3 long-term extension trial ESTUARY showed that clinical responses in patients aged 12 years and older could be maintained over the long term without relapse, while the safety profile remained consistent with existing data. However, after assessing the efficacy and safety evidence accumulated to date as a whole, the company still determined that amlitelimab was insufficient to clearly improve the current standard of care for atopic dermatitis and therefore would not proceed with regulatory submissions.
This decision highlights that the bar for late-stage drug development is not limited to outperforming placebo. With multiple biologics and oral targeted therapies already available for atopic dermatitis, a new candidate must also establish sufficiently clear differentiation in areas such as the degree of skin clearance, symptom control, safety, dosing convenience, or durability of efficacy to have a chance of securing a clinical and commercial position.
Complete data sufficient to independently assess this decision are still lacking. In its announcement, Sanofi did not provide ESTUARY’s specific response rates, assessment time points, comparator-group results, or detailed adverse-event data, nor did it identify any particular safety signal as the direct reason for terminating the program. The company expects to disclose more results at future medical conferences. Until then, it can only be confirmed that this was a strategic judgment based on the overall benefit–risk profile and competitiveness, and it cannot be reduced to the failure of a single trial.
Sanofi will gradually wind down the ongoing atopic dermatitis studies and coordinate with trial investigators, study centers, and regulatory authorities to ensure continuity of care for participants. The decision does not affect the company’s full-year 2026 financial outlook. Amlitelimab has also not been completely removed from development: a phase 2 trial in nonresponsive celiac disease remains ongoing, with results expected in the second half of 2026.